7 recruiting, 3 active not recruiting, 2 terminated, 1 completed. 14 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Recruiting 7, Active not recruiting 3, Terminated 2, Completed 1, Withdrawn 1 |
| Phase 2 | 7 | Active not recruiting 2, Recruiting 2, Terminated 2, Completed 1 |
Follow Recurrent Chronic Myelomonocytic Leukemia: new trials by email Literature Review of Recurrent Chronic Myelomonocytic Leukemia trials Research Report on Recurrent Chronic Myelomonocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| Q702 for the Treatment of Patients With Hematologic Malignancies Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration - Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma | Phase 1 | Recruiting | Mayo Clinic | 46 | 2025-08-27 | 2025-10-10 |
| Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Onvansertib - Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 25 | 2023-04-04 | 2026-06-22 |
| Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Azacitidine, Seclidemstat - Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1 | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 24 | 2021-07-07 | 2026-09-18 |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia DS-1594b, Azacitidine, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 17 | 2021-03-25 | 2025-05-23 |
| CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia Cladribine, Cyclophosphamide, Cyclosporine - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 120 | 2020-12-03 | 2026-09-17 |
| Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Azacitidine, Venetoclax - Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 34 | 2020-09-04 | 2026-06-05 |
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations Azacitidine, Quizartinib - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2020-07-21 | 2026-10-05 |
| Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Rivogenlecleucel, Rimiducid - Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2020-01-02 | 2020-08-14 | |
| Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm Azacitidine, Gilteritinib, Venetoclax - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 97 | 2019-12-17 | 2026-10-06 |
| CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Liposome-encapsulated Daunorubicin-Cytarabine - Blasts 10-19 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 38 | 2019-05-14 | 2026-10-06 |
| Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Laboratory Biomarker Analysis, Pharmacological Study - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 72 | 2019-01-31 | 2026-09-18 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection - Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 24 | 2018-02-23 | 2026-05-18 |
| Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Azacitidine, Cytarabine, Quizartinib - FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 73 | 2013-11-12 | 2026-10-23 |
Leukemia, Myelomonocytic, Chronic (14) · Myelodysplastic Syndromes (10) · Leukemia, Myeloid, Acute (8) · Leukemia, Biphenotypic, Acute (4) · Blastic Plasmacytoid Dendritic Cell Neoplasm (3) · Myelodysplastic-Myeloproliferative Diseases (3) · Myeloproliferative Disorders (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Blast Crisis (2) · Hematologic Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Primary Myelofibrosis (2) · Dendritic Cell Sarcoma, Interdigitating (1) · Erdheim-Chester Disease (1)
Bone Marrow Diseases (14) · Chronic Disease (14) · Disease Attributes (14) · Hematologic Diseases (14) · Hemic and Lymphatic Diseases (14) · Leukemia, Myeloid (14) · Neoplasms (14) · Neoplasms by Histologic Type (14) · Pathologic Processes (14) · Pathological Conditions, Signs and Symptoms (14) · Leukemia (13) · Myelodysplastic-Myeloproliferative Diseases (11) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Leukemia, Lymphoid (6)
Azacitidine (6) · Cytarabine (5) · Biopsy (3) · Filgrastim (3) · Granulocyte Colony-Stimulating Factor (3) · Specimen Handling (3) · venetoclax (3) · Cyclophosphamide (2) · Hematopoietic Stem Cell Transplantation (2) · Idarubicin (2) · Injections (2) · Stem Cell Transplantation (2) · Whole-Body Irradiation (2) · X-Rays (2) · fludarabine (2)
M.D. Anderson Cancer Center (8) · Fred Hutchinson Cancer Center (4) · Mayo Clinic (2)
United States (14)
Guillermo M Bravo (3) · Elizabeth Krakow (2) · Filippo Milano (1) · Guillermo Garcia-Manero (1) · Jithma P. Abeykoon, MD (1) · Mrinal S. Patnaik, MBBS (1) · Naval G Daver, MD (1) · Naveed Ali, MD (1) · Nicholas Short (1) · Tapan M Kadia (1) · Yesid Alvarado, MD (1)
PMID 36841758, PMID 37946611, PMID 38277619, PMID 38683966, PMID 38744144, PMID 42200455
P30CA015704 (2), P50CA100632 (1), R01CA272496 (1)